Evidence map›Paper›PMID 34039257›Full record

ReviewMolecular medicine (Cambridge, Mass.)2021

Role of long noncoding RNA taurine-upregulated gene 1 in cancers.

Miao Da, Jing Zhuang, Yani Zhou, Quan Qi, Shuwen Han

Open access · goldAbstract readReview
In one paragraph

Review in Molecular medicine (Cambridge, Mass.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Progress on long non-coding RNAs in calcific aortic valve disease.Frontiers in cardiovascular medicine · 2025
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024
    Review
  16. Article
  17. Review
  18. Non-Coding RNAs as Key Regulators in Lung Cancer.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Miao DaDepartment of Nursing, Huzhou Third Municipal Hospital, 2088 East Tiaoxi Rd, Huzhou, Zhejiang, People's Republic of China.
Jing ZhuangMedical College of Nursing, Huzhou University, No. 759 Erhuan East Road, Huzhou, 313000, Zhejiang, China.
Yani ZhouGraduate School of Medicine Faculty, Zhejiang University, No. 866 Yuhangtang Road, Xihu, Hangzhou, 310058, Zhejiang, People's Republic of China.
Quan QiDepartment of Oncology, Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, No. 1558, Sanhuan North Road, Wuxing, Huzhou, 313000, Zhejiang, China.
Shuwen HanDepartment of Oncology, Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, No. 1558, Sanhuan North Road, Wuxing, Huzhou, Zhejiang, People's Republic of China. ww@hzhospital.com.ORCID 0000-0001-6180-9565
Huzhou University · CNThird People's Hospital of Huzhou · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) are a group of non-protein coding RNAs with a length of more than 200 bp. The lncRNA taurine up-regulated gene 1 (TUG1) is abnormally expressed in many human malignant cancers, where it acts as a competitive endogenous RNA (ceRNA), regulating gene expression by specifically sponging its corresponding microRNAs. In the present review, we summarised the current understanding of the role of lncRNA TUG1 in cancer cell proliferation, metastasis, angiogenesis, chemotherapeutic drug resistance, radiosensitivity, cell regulation, and cell glycolysis, as well as highlighting its potential application as a clinical biomarker or therapeutic target for malignant cancer. This review provides the basis for new research directions for lncRNA TUG1 in cancer prevention, diagnosis, and treatment.

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticAnimalsApoptosisCell CycleCell Line, TumorCell MovementCell ProliferationDisease SusceptibilityHumansNeoplasm InvasivenessNeoplasm MetastasisNeoplasmsNeovascularization, PathologicRNA, Long NoncodingSignal TransductionBiomarkers, TumorRNA, Long NoncodingTUG1 long noncoding RNA, humanBiomarkerCancerCompetitive endogenous RNA (ceRNA)Long non-coding RNA (lncRNA)Taurine‐upregulated gene 1 (TUG1)

Identifiers

PMID34039257
PMCPMC8157665
OpenAlexW3165183154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.